NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly-Informed Integrated Immunotherapy Combining Innate High-Affinity Natural Killer (haNK) Cell Therapy with Adenoviral & Yeast-based Vaccines and Immune Checkpoint Inhibitor to Induce T-Cell Responses in Subjects with TNBC Who Have Progressed on or after Standard-of-Care Therapy
Mechanisms of resistance to T cell-based immunotherapy in head and neck cancer
Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma
